Posted on 21/05/2009 in Pharmaceutical Company Product News Almirall's Sativex will be an interesting addition to its central nervous system pipeline, it has stated.
Following positive results in a phase III clinical trial, the company has filed a regulatory submission regarding the drug to the UK and Spain.
The Medicines and Healthcare products Regulatory Agency has validated the treatment, which is intended to aid spasticity due to multiple sclerosis.
An outcome of the submission should be known towards the end of 2009 or the beginning of next year and if it is permitted in the UK and Spain, further applications will be made across the continent.
Luciano Conde, chief operating officer at Almirall, noted the drug is the first new treatment to relieve symptoms of the condition in ten years.
"[This is] encouraging news for patients suffering of spasticity due to multiple sclerosis," he remarked.
Earlier this month, Almirall launched the type 2 diabetes drug Efficib (sitagliptin and metformin combination in a single tablet) in Spain.
Merck Sharp & Dohme granted the company rights to market the medication in the country under this trademark.
It is intended to be used alongside exercise and diet to improve glycemic control.Other news stories from 21/05/2009
Read more in the Zenopa News Archive
How this news is generated
|
